New cancer pill targets Tough-to-Treat tumors
NCT ID NCT05593094
Summary
This early-stage study is testing a new oral medication called ZN-A-1041 for people with advanced HER2-positive cancers that have spread or returned after treatment. Researchers will give the drug alone or combined with other standard cancer therapies to about 210 participants to find safe doses and see if it helps control tumor growth. The study is specifically looking at cancers that have spread, including to the brain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa
Tucson, Arizona, 85712, United States
-
Asst Papa Giovanni XXIII
Bergamo, Lombardy, 24127, Italy
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Centre Georges Francois Leclerc
Dijon, 21000, France
-
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Clatterbridge Cancer Centre
Liverpool, Merseyside, L69 3GL, United Kingdom
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University School of Medicine
Durham, North Carolina, 27710, United States
-
EDOG - Institut Claudius Regaud - PPDS
Toulouse, Haute-Garonne, 31059, France
-
Fondazione Policlinico Universitario A Gemelli-Rome
Magnago, Lombardy, 20020, Italy
-
Fundacion Instituto Valenciano de Oncologia (IVO)
Valencia, 46009, Spain
-
Geelong Hospital
Geelong, Victoria, 3220, Australia
-
Gustave Roussy
Villejuif, 94800, France
-
Hospital Beata Maria Ana
Madrid, 28007, Spain
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico San Carlos
Madrid, 28040, Spain
-
Hospital Clinico Universitario de Santiago
Santiago de Compostela, LA Coruna, 15706, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Ramon y Cajal
A Gudiña, Orense, 32540, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Hospital Universitario Virgen del Rocio
Las Cabezas de San Juan, Sevilla, 41730, Spain
-
Hospital Universitario de Jaen
Jaén, 23007, Spain
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Institut de Cancerologie de l Ouest
Saint-Herblain, 44805, France
-
Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud
Barcelona, 08028, Spain
-
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Argentona, Barcelona, 08310, Spain
-
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS
Parma, Emilia-Romagna, 43126, Italy
-
MD Anderson Cancer Center
Houston, Texas, 77030-4000, United States
-
Sunshine Hospital
St Albans, Victoria, 3021, Australia
-
TOI Clinical Research
Cerritos, California, 90703-2684, United States
-
The Christie
Manchester, Lancashire, M20 4BX, United Kingdom
-
UCSF Helen Diller Family CCC
San Francisco, California, 94158, United States
-
University of Michigan Hospital
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.